Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

<p>Tumor response, OS, and PFS. <b>A</b> and <b>B,</b> A summary of (<b>A</b>) best reduction and (<b>B</b>) percent change from baseline in the sum of the diameters of target tumors in each patient with NSCLC treated with nivolumab. <b>C&l...

Mô tả đầy đủ

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Kohei Shitara (15043443) (author)
Tác giả khác:	Motohiro Tamiya (17866315) (author), Kyoichi Okishio (17866312) (author), Hisashi Hosaka (22420197) (author), Katsunori Shinozaki (22420200) (author), Nobuhiko Seki (22420203) (author), Hiroki Hara (15026339) (author), Yukiya Narita (22420206) (author), Takeshi Shiraishi (22420209) (author), Yosuke Tamura (22420212) (author), Akihito Tsuji (21430589) (author), Kunihiro Tsuji (22420215) (author), Naohiro Watanabe (22420218) (author), Hiroshi Tanaka (15014300) (author), Toshifumi Yamaguchi (22420221) (author), Kensei Yamaguchi (15054104) (author), Hiroki Izumi (15047559) (author), Yasunori Ushida (22420224) (author), Hideaki Suna (22420227) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Immuno-oncology Clinical Research and Trials Biomarkers For Immunotherapy Clinical Trial Results Phase II clinical trials Checkpoint Blockade Gastrointestinal Cancers Stomach cancer Lung Cancer
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!